Get the Stockscreener App
1.62
3.51%
0.055
After Hours:
1.70
0.08
+4.94%
Nervgen Pharma Corp stock is traded at $1.62, with a volume of 474.19K.
It is up +3.51% in the last 24 hours and down -24.30% over the past month.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
See More
Previous Close:
$1.565
Open:
$1.59
24h Volume:
474.19K
Relative Volume:
1.06
Market Cap:
$174.19M
Revenue:
Net Income/Loss:
$-31.64M
P/E Ratio:
-3.8334
EPS:
-0.4226
Net Cash Flow:
$-13.98M
1W Performance:
-7.43%
1M Performance:
-24.30%
6M Performance:
-61.79%
1Y Performance:
+0.00%
1-Day Range:
$1.55
$1.66
1-Week Range:
$1.55
$1.80
52-Week Range:
$1.55
$6.30
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
1.62 | 174.19M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-26 | Initiated | Leerink Partners | Outperform |
| Jun-11-26 | Initiated | TD Cowen | Buy |
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
Nervgen Pharma Corp Stock (NGEN) Latest News
NervGen Pharma (Nasdaq:NGEN)Stock Analysis - Simply Wall Street
Diluted net income available to common stockholders of NervGen Pharma Corp. – HAN:9UA - TradingView
NervGen Pharma Corp. Statistics – HAN:9UA - TradingView
What Does NervGen Pharma's (NASDAQ:NGEN) Latest Move Mean for Penny Stocks Investors? - kalkinemedia.com
NervGen to Host Inaugural R&D Day on September 30, 2026 - marketscreener.com
Four experts join a live spinal cord research webcast - Stock Titan
Can NervGen Pharma (TSXV:NGEN) Advance Canada’s Biotech Story? - Kalkine Media
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Barchart.com
NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021 - TMX Newsfile
NervGen Pharma Receives Investment from Drug Manufacturing Partner - TMX Newsfile
NervGen (NGEN) Results Check: The Available Figures Are Largely in Line in the Latest Session; Post-Earnings: Shares Rise 4.30% at the CloseEarnings Momentum Score - careplusvn.com
What Makes NervGen Pharma (TSXV:NGEN) A Biotech Watchlist Name? - Kalkine Media
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest TradingEarnings Surprise Score - vinanet.vn
NervGen (NGEN) Earnings Update: Available Metrics Are Broadly Near Expectations in the Latest Reading; Stock Move - vinanet.vn
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest TradingManagement Guidance Update - careplusvn.com
NervGen (NGEN) Earnings Update: Available Metrics Are Broadly Near Expectations in the Latest Reading; Stock Move - dars.gov.et
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest TradingEarnings Surprise Score - dars.gov.et
NervGen (NGEN) Earnings Update: Available Metrics Are Broadly Near Expectations in the Latest Reading; Stock Move - www.dars.gov.et
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest TradingRevenue Per Share - https://www.dars.gov.et/
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX) - The Globe and Mail
NervGen Pharma (NGEN) Advances RESTORE Study with FDA Backing, F - GuruFocus
NervGen Pharma (HAM:9UA) Cyclically Adjusted PS Ratio : (As of Aug. 16, 2026) - GuruFocus
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
NervGen Pharma (NGEN) Dips 1.4% to $1.74, Holds Above Key SupportAndrews Pitchfork - dars.gov.et
NervGen Pharma (NGEN) Dips 1.4% to $1.74, Holds Above Key SupportLarge Cap Trends - vinanet.vn
NervGen Pharma (NGEN) Dips 1.4% to $1.74, Holds Above Key SupportIchimoku Kumo Twist - dars.gov.et
NGEN: RESTORE Phase 3 trial advances with robust funding and FDA alignment; Q2 net loss widens - TradingView
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Caledonian Record
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com
NervGen Q2 FY26 net loss widens to C$29.2 million - Bitget
NGEN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NervGen Pharma (NGEN) Q3 2025 Earnings: Narrower-than-Expected Loss as Pipeline Development ContinuesFinancial Summary - dars.gov.et
NervGen Pharma (NGEN) Edges Higher to $1.62, Holding Above Key Support LevelBackspread Trade - vinanet.vn
NGEN Q3 2025 Earnings: Narrower Net Loss Brings a 0.99 Percent Positive SurpriseEBITDA Estimate Trend - vinanet.vn
NervGen Pharma (NGEN) Holds Near Support as Price Pullback Tests Key LevelsMoney Flow - dars.gov.et
Oramed Pharmaceuticals Market Sentiment - Benzinga
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nervgen Pharma Ord Shs (NGEN) Balance Sheet - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Income Statement - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.640|Chg%:+0.010 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Cash Flow - TradingKey
NervGen Pharma Corp. Revenue Breakdown – NASDAQ:NGEN - TradingView
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.630|Chg%:-0.045 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NGEN Q3 2025 Earnings: Narrower Loss Surprises as Clinical Pipeline Progress ContinuesEarnings Weakness Phase - vinanet.vn
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nervgen Pharma Corp Stock (NGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):